[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Neuroscience Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100488750","restores-trial-restoration-of-rehabilitative-function-with-epidural-spinal-stimulation-100488750",false,"NCT05644171","RESTORES Trial: RESToration Of Rehabilitative Function With Epidural Spinal Stimulation","RS-01","⦁ Inclusion Criteria\n\nFor inclusion in the study, the potential patient has to fulfil all of the following criteria:\n\n1. 21 years old and older\n2. Chronic (greater than one year) motor complete (AIS classification A or B) SCI\n3. Spinal injury between the levels of Cervical 2 (C2) to Thoracic 12 (T12)\n4. Segmental reflexes that remain functional below the level of lesion\n5. Able to perform the perioperative rehabilitation program as judged by the research team\n\n   * Exclusion Criteria\n\nPotential patients will be excluded from the trial if they fulfil any of the following criteria:\n\n1. Significant medical co-morbidities that would significantly increase the risk of the operation\n2. Severe dysautonomia with systolic blood pressure fluctuation less than 50 or more than 200mmHg on tilt table testing\n3. Painful musculoskeletal dysfunction, contractures, unhealed fractures, pressure sores, severe spasticity, and osteoporosis\n4. Significant psychological issues or ongoing drug abuse\n5. Pregnancy and lactating patients\n6. Progressive spinal cord disease","ALL","21 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"NA","Spinal Cord Injury (SCI), being a devastating diagnosis, has little to no recovery which leads to a long-standing of debilitating impairment for affected patients. The NNI Neurosurgery team, together with our collaborators, are expanding our recruitment from our pilot trial named RESTORES: RESToration of Rehabilitative function with Epidural Spinal Stimulation. This study aims to investigate the feasibility of electrical stimulation via a spinal cord stimulator (SCS), which will be implanted into the study subjects, and advanced robotic neurorehabilitation to aid in improving neurological function in patients diagnosed with chronic SCI. An additional 15 patients on top of the 3 ongoing patients, male and female participants, above the age of 21 who have been diagnosed with the condition for more than a year will be recruited for this study over a 2-year period. Rehab sessions will take place pre and post-surgical implant, assessing subject improvements",[26],"Chronic Spinal Cord Injury",[28,29,30],"Spinal cord injury","Epidural spinal stimulation","Implantation","RECRUITING","2026-01-23",{"date":34,"type":35},"2026-01-26","ACTUAL",{"date":37,"type":35},"2022-12-19",{"date":39,"type":20},"2031-12-30",{"name":41,"class":42},"National Neuroscience Institute","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":43},"100402812","phase-2-egb-761-in-the-syndrome-of-mci-with-concomitant-cvd-100402812","NCT04525144","EGb 761 in the Syndrome of MCI With Concomitant CVD","Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)","Inclusion Criteria:\n\n* Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria\n* Patients who have a Global Clinical Dementia Rating Score of 0.5\n* Patients aged 45 to 85 years at study entry\n* Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators\n* Patients with the presence of CVD, defined as the presence of white matter hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12 months prior to recruitment) or CT scans for patients contraindicated from MRI scans\n* Patients who provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information\u002FSummary of Product Characteristics (SmPC) should be observed.","45 Years","85 Years",{"count":54,"type":20},134,[56],"PHASE2","EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.",[59,60],"Mild Cognitive Impairment","Cerebrovascular Disease","2022-11-14",{"date":63,"type":35},"2022-11-17",{"date":65,"type":35},"2020-10-26",{"date":67,"type":20},"2026-11",{"name":41,"class":42},""]